NASDAQ$PRCT
PROCEPT BioRobotics Corporation · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
PROCEPT BioRobotics experienced substantial revenue growth, driven by strong U.S. sales and increased adoption of Aquablation therapy.
PROCEPT BioRobotics reported a strong fourth quarter with a 135% increase in revenue compared to the prior year period. The company's U.S. system and consumable sales drove growth, and the installed base of AquaBeam Robotic Systems in the U.S. reached 167. The company issued 2023 total revenue guidance of approximately $125 million.
- Total revenue for Q4 2022 was $23.8 million, a 135% increase year-over-year.
- U.S. system and rental revenue increased by 109% to $10.4 million in Q4 2022.
- U.S. handpiece and consumables revenue grew by 202% to $10.4 million in Q4 2022.
- The company projects revenue for the full year 2023 to be approximately $125 million.
Headline financials
Revenue & EPS history
PROCEPT BioRobotics · Revenue · Quarterly
$23.8M
Revenue by segment
PROCEPT BioRobotics · $20.8M total across 2 segments · Q4 2022
- U.S. System Sales$10.4M+108.6%50.2%
- U.S. Consumables$10.4M+201.6%49.8%
Forward guidance
The Company projects revenue for the full year 2023 to be approximately $125 million and full year 2023 gross margin to be approximately 53%.
Tailwinds
- Revenue for the full year 2023 is projected to be approximately $125 million, representing 67% growth over the prior year.
- Full year 2023 gross margin is projected to be approximately 53%.
Headwinds
- Full year 2023 total operating expense is projected to be approximately $163 million.
- Full year 2023 Adjusted EBITDA loss is projected to be approximately $70.5 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+1.3%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+0.6%
Avg return
30 days after
45%
10 / 22 earnings
Positive
+40.6%
Q3 2024
Best reaction
-15.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.7% | +16.0% | +21.3% | |
| Q4 2025 | -15.2% | -5.7% | -5.3% | |
| Q3 2025 | +1.6% | -7.5% | +2.7% | |
| Q1 2025 | -5.6% | +1.1% | +3.0% | |
| Q4 2024 | +8.6% | -3.4% | -4.2% | |
| Q3 2024 | +40.6% | +34.2% | +41.5% | |
| Q2 2024 | -9.4% | -4.3% | +24.8% | |
| Q1 2024 | +16.5% | +15.9% | +25.3% | |
| Q4 2023 | +1.1% | +0.5% | +1.2% | |
| Q3 2023 | +21.7% | +22.5% | +39.5% | |
| Q2 2023 | -6.7% | -10.3% | -18.4% | |
| Q1 2023 | -15.0% | -20.1% | -10.9% | |
| Q4 2022 | +1.2% | -4.3% | -28.7% | |
| Q3 2022 | -9.9% | -8.4% | +5.8% | |
| Q2 2022 | +4.3% | +4.3% | +0.2% | |
| Q1 2022 | -5.1% | -17.9% | +19.5% | |
| Q4 2021 | +1.2% | +5.9% | +38.7% | |
| Q3 2020 | -2.2% | -4.5% | -28.0% | |
| Q4 2020 | -2.2% | -4.5% | -28.0% | |
| Q2 2021 | -2.2% | -4.5% | -28.0% | |
| Q1 2021 | -2.2% | -4.5% | -28.0% | |
| Q3 2021 | -4.4% | -3.9% | -29.6% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro